IL5 and asthma: For Global Initiative for Asthma (GINA) Step 5 patients, a targeted therapy approach is recommended; omalizumab, a humanised mAb that selectively targets IgE, and mepolizumab and reslizumab, two additional humanised mAbs targeting IL-5, are available treatment options [16, 17].